Literature DB >> 22144662

Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Guang Yang1, Alexei A Goltsov, Chengzhen Ren, Shinji Kurosaka, Kohei Edamura, Richard Logothetis, Francesco J DeMayo, Patricia Troncoso, Jorge Blando, John DiGiovanni, Timothy C Thompson.   

Abstract

Previously we reported caveolin-1 (Cav-1) overexpression in prostate cancer cells and showed that it promotes prostate cancer progression. Here, we report that Cav-1 was overexpressed in 41.7% (15 of 36) of human high-grade prostatic intraepithelial neoplasia (HGPIN) specimens obtained during radical prostatectomies. Positive correlations exist between Cav-1-positive (Cav-1(+)) HGPIN and Cav-1(+) primary prostate cancer (rho = 0.655, P < 0.0001) and between Cav-1 and c-Myc expression in HGPIN (rho = 0.41, P = 0.032). To determine whether Cav-1 cooperates with c-Myc in development of premalignant lesions and prostate cancer in vivo, we generated transgenic mice with c-Myc overexpression driven by the ARR(2)PB promoter. In this ARR(2)PB-c-myc model, Cav-1 overexpression was found in mouse PIN (mPIN) lesions and prostate cancer cells and was associated with a significantly higher ratio of proliferative to apoptotic labeling in mPIN lesions than in the Cav-1-negative epithelia adjacent to those lesions (10.02 vs. 4.34; P = 0.007). Cav-1 overexpression was also associated with increased levels of P-Akt and VEGF-A, which were previously associated with Cav-1-induced prostate cancer cell survival and positive feedback regulation of cellular Cav-1 levels, respectively. In multiple prostate cancer cell lines, Cav-1 protein (but not mRNA) was induced by c-Myc transfection, whereas VEGF siRNA transfection abrogated c-Myc-induced Cav-1 overexpression, suggesting a c-Myc-VEGF-Cav-1 signaling axis. Overall, our results suggest that Cav-1 is associated with c-Myc in the development of HGPIN and prostate cancer. Furthermore, Cav-1 overexpression in HGPIN is potentially a biomarker for early identification of patients who tend to develop Cav-1(+) primary prostate cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144662      PMCID: PMC3908884          DOI: 10.1158/1541-7786.MCR-11-0451

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  38 in total

Review 1.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

2.  Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol.

Authors:  A Bist; P E Fielding; C J Fielding
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.

Authors:  G Yang; L D Truong; T M Wheeler; T C Thompson
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

4.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

5.  Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells.

Authors:  Y Nasu; T L Timme; G Yang; C H Bangma; L Li; C Ren; S H Park; M DeLeon; J Wang; T C Thompson
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

6.  Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation.

Authors:  Pau Mezquita; Sean S Parghi; Kimberly A Brandvold; Alanna Ruddell
Journal:  Oncogene       Date:  2005-01-27       Impact factor: 9.867

7.  Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B.

Authors:  Z Q Ma; S S Chua; F J DeMayo; S Y Tsai
Journal:  Oncogene       Date:  1999-08-12       Impact factor: 9.867

8.  Elevated expression of caveolin is associated with prostate and breast cancer.

Authors:  G Yang; L D Truong; T L Timme; C Ren; T M Wheeler; S H Park; Y Nasu; C H Bangma; M W Kattan; P T Scardino; T C Thompson
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

Review 9.  A matter of life and cell death.

Authors:  G Evan; T Littlewood
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

10.  The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis.

Authors:  J L Rohn; A O Hueber; N J McCarthy; D Lyon; P Navarro; B M Burgering; G I Evan
Journal:  Oncogene       Date:  1998-12-03       Impact factor: 9.867

View more
  20 in total

1.  Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Authors:  Spyridon P Basourakos; John W Davis; Brian F Chapin; John F Ward; Curtis A Pettaway; Louis L Pisters; Neema Navai; Mary F Achim; Xuemei Wang; Hsiang-Chun Chen; Seungtaek Choi; Deborah Kuban; Patricia Troncoso; Sam Hanash; Timothy C Thompson; Jeri Kim
Journal:  BJU Int       Date:  2017-08-16       Impact factor: 5.588

2.  Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models.

Authors:  Tetsuo Fujita; Takefumi Satoh; Terry L Timme; Takahiro Hirayama; Julie X Zhu; Nobuyuki Kusaka; Koji Naruishi; Guang Yang; Alexei Goltsov; Jianxiang Wang; Maria T Vlachaki; Bin S Teh; E Brian Butler; Timothy C Thompson
Journal:  Urol Oncol       Date:  2013-02-20       Impact factor: 3.498

3.  Up-regulation of AKAP13 and MAGT1 on cytoplasmic membrane in progressive hepatocellular carcinoma: a novel target for prognosis.

Authors:  Patamaporn Molee; Poom Adisakwattana; Onrapak Reamtong; Songsak Petmitr; Thaniya Sricharunrat; Nantana Suwandittakul; Urai Chaisri
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Caveola-forming proteins caveolin-1 and PTRF in prostate cancer.

Authors:  Zeyad D Nassar; Michelle M Hill; Robert G Parton; Marie-Odile Parat
Journal:  Nat Rev Urol       Date:  2013-08-13       Impact factor: 14.432

Review 5.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

Review 6.  Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Authors:  Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

7.  GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.

Authors:  Styliani Karanika; Theodoros Karantanos; Shinji Kurosaka; Jianxiang Wang; Takahiro Hirayama; Guang Yang; Sanghee Park; Alexei A Golstov; Ryuta Tanimoto; Likun Li; Timothy C Thompson
Journal:  Mol Cancer       Date:  2015-06-19       Impact factor: 27.401

8.  miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1.

Authors:  Henriett Butz; Peter M Szabó; Heba W Z Khella; Roy Nofech-Mozes; Attila Patocs; George M Yousef
Journal:  Oncotarget       Date:  2015-05-20

9.  Caveolin-1 limits the contribution of BKCa channel to MCF-7 breast cancer cell proliferation and invasion.

Authors:  Cheng Du; Li Chen; Haijun Zhang; Zhongchao Wang; Wenchao Liu; Xiaodong Xie; Manjiang Xie
Journal:  Int J Mol Sci       Date:  2014-11-12       Impact factor: 5.923

10.  Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review).

Authors:  Dali Chen; Guowei Che
Journal:  Oncol Lett       Date:  2014-07-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.